Literature DB >> 6625384

Drugs five years later. Dobutamine.

C V Leier, D V Unverferth.   

Abstract

Dobutamine is a synthetic catecholamine developed as a relatively selective positive inotropic drug for short-term parenteral administration. Dobutamine's effects are mediated by strong beta 1 adrenergic receptor stimulation and mild stimulation of beta 2 and alpha 1 receptors. Dobutamine should be used to improve ventricular function and cardiac performance in patients in whom ventricular dysfunction has caused a reduced stroke volume and cardiac output, a mild to moderate drop in systemic blood pressure, diminished organ and tissue perfusion, and elevated ventricular filling pressures. When guidelines for patient selection and dosing are adhered to, ventricular dysfunction and cardiac decompensation secondary to atherosclerotic occlusive coronary artery disease can be improved without adversely affecting the myocardial oxygen supply and demand balance. Dobutamine has less vasopressor activity than norepinephrine and dopamine, and should not be the primary treatment in conditions characterized by marked hypotension and shock.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6625384     DOI: 10.7326/0003-4819-99-4-490

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  24 in total

1.  Prevention of bedrest-induced physical deconditioning by daily dobutamine infusions. Implications for drug-induced physical conditioning.

Authors:  M J Sullivan; P F Binkley; D V Unverferth; J H Ren; H Boudoulas; T M Bashore; A J Merola; C V Leier
Journal:  J Clin Invest       Date:  1985-10       Impact factor: 14.808

2.  Therapeutic strategies in congestive heart failure and the new inotrope-vasodilator agents.

Authors:  C A Simonton
Journal:  West J Med       Date:  1985-02

3.  Comparison of the cardiodynamic and metabolic effects of dobutamine with those of norepinephrine and dopamine in the dog isolated heart.

Authors:  J A Simaan; G Fawaz; K Jabbour
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-08       Impact factor: 3.000

4.  Dobutamine 99mTc-MIBI single-photon emission tomography: non-exercise-dependent detection of haemodynamically significant coronary artery stenoses.

Authors:  E Voth; F M Baer; P Theissen; C A Schneider; U Sechtem; H Schicha
Journal:  Eur J Nucl Med       Date:  1994-06

5.  Intravenous fenoldopam infusion in severe heart failure.

Authors:  J J Patel; A S Mitha; P Sareli; J B de Vaal
Journal:  Cardiovasc Drugs Ther       Date:  1993-02       Impact factor: 3.727

6.  The elusive link between coronary lesion morphology and dobutamine stress echocardiography results. The EDIC (Echo Dobutamine International Cooperative) Study Group.

Authors:  J Heyman; P Salvadé; E Picano; A Varga; E Gliozheni; R Sicari; M Previtali; G Rovelli
Journal:  Int J Card Imaging       Date:  1997-10

Review 7.  The pharmacokinetics and pharmacodynamics of newer inotropic agents.

Authors:  M L Rocci; H Wilson
Journal:  Clin Pharmacokinet       Date:  1987-08       Impact factor: 6.447

8.  Interactions of three inotropic agents, ASL-7022, dobutamine and dopamine, with alpha- and beta-adrenoceptors in vitro.

Authors:  R R Ruffolo; K Messick; J S Horng
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-07       Impact factor: 3.000

Review 9.  Intravenous vasodilator therapy in congestive heart failure.

Authors:  Kourosh Moazemi; Jatinder S Chana; Anna Marie Willard; Abraham G Kocheril
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

10.  Effects of dobutamine on left ventricular performance in newborns as determined by systolic time intervals.

Authors:  H Stopfkuchen; D Schranz; R Huth; B K Jüngst
Journal:  Eur J Pediatr       Date:  1987-03       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.